



## Table of Contents: EU REACH Substance communication

<b>English</b> .....	<b>2</b>
<b>French</b> .....	<b>5</b>
<b>Bulgarian</b> .....	<b>8</b>
<b>Czech</b> .....	<b>11</b>
<b>Spanish</b> .....	<b>14</b>
<b>Danish</b> .....	<b>17</b>
<b>German</b> .....	<b>20</b>
<b>Estonian</b> .....	<b>23</b>
<b>Greek</b> .....	<b>26</b>
<b>Croatian</b> .....	<b>29</b>
<b>Italian</b> .....	<b>32</b>
<b>Latvian</b> .....	<b>35</b>
<b>Lithuanian</b> .....	<b>38</b>
<b>Hungarian</b> .....	<b>41</b>
<b>Maltese</b> .....	<b>44</b>
<b>Dutch</b> .....	<b>47</b>
<b>Polish</b> .....	<b>50</b>
<b>Portuguese</b> .....	<b>53</b>
<b>Romanian</b> .....	<b>56</b>
<b>Slovak</b> .....	<b>59</b>
<b>Slovenian</b> .....	<b>62</b>
<b>Finnish</b> .....	<b>65</b>
<b>Swedish</b> .....	<b>68</b>



## GE Healthcare

**Surya Kunduri**  
 REACH Regulations Leader  
 Product Compliance Engineering  
 Suryadutt.Kunduri@ge.com  
 M +33 664083106

**Yachun Du**  
 Senior Architect  
 GEHC X Ray Engineering  
 Yachun.du@ge.com  
 M +86 10 57083340

GE Healthcare works with its suppliers to ensure compliance of articles imported or manufactured within the European Union that are subject to the REACH regulation (EC- No 1907/2006), Article 33, and used in the production of GE Healthcare products.

Regarding the application of Article 33 of the REACH regulation and the publication of the Candidate List of Substances of Very High Concern (SVHC) according to Article 59 of REACH regulation, GE Healthcare is aware of its legal obligations and will comply with them.

GE Healthcare articles do not "intentionally release" substances under normal conditions of use. Based on information from our suppliers to date, these substances are present in the following products at a concentration greater than the threshold of 0.1% (w/w) at the article level:

Product	EU REACH Candidate List Substance	CAS Number
XR240amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Cadmium oxide (CdO)	1306-19-0
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro-1,4,4a,5,6,6a,7,10,10a,11,12,12a-dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5-methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5-tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro-1,3-dioxo-	552-30-7
Lead	7439-92-1	
Cadmium	7440-43-9	
XR220amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro-1,4,4a,5,6,6a,7,10,10a,11,12,12a-dodecahydro-	13560-89-9



	1,3-Isobenzofurandione, hexahydro-5-methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5-tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro-1,3-dioxo-	552-30-7
	Lead	7439-92-1
	Cadmium	7440-43-9
XR200amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro-1,4,4a,5,6,6a,7,10,10a,11,12,12a-dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5-methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5-tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro-1,3-dioxo-	552-30-7
	Lead	7439-92-1
	Cadmium	7440-43-9
Brivo XR285	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro-1,4,4a,5,6,6a,7,10,10a,11,12,12a-dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5-methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5-tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro-1,3-dioxo-	552-30-7
	Lead	7439-92-1
	Cadmium	7440-43-9
AMX 4/4+/700	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2



	Lead oxide (PbO)	1317-36-8
Discovery XR656	Lead	7439-92-1
	1,3-Isobenzofurandione, hexahydromethyl-	25550-51-0
	Boron oxide (B2O3)	1303-86-2
	Lead titanium zirconium oxide (Pb(Ti,Zr)O3)	12626-81-2
	Silicic acid, lead salt	11120-22-2
Optima XR646	Lead oxide (PbO)	1317-36-8
	Boron oxide (B2O3)	1303-86-2
	Lead titanium zirconium oxide (Pb(Ti,Zr)O3)	12626-81-2
	Silicic acid, lead salt	11120-22-2
	Lead	7439-92-1
	1,3-Isobenzofurandione, hexahydromethyl-	25550-51-0
	1,3-Isobenzofurandione, hexahydro-5-methyl-	19438-60-9
Brivo XR575	Silicic acid, lead salt	11120-22-2
Proteus XR/a	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead	7439-92-1
XR6000	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
Brivo XR118	Silicic acid, lead salt	11120-22-2
WDR1	Silicic acid, lead salt	11120-22-2
	Lead	7439-92-1



## GE Healthcare

**Surya Kunduri**  
REACH Regulations Leader  
Product Compliance Engineering  
Suryadutt.Kunduri@ge.com  
M +33 664083106

**Yachun Du**  
Senior Architect  
GEHC X Ray Engineering  
Yachun.du@ge.com  
M +86 10 57083340

GE Healthcare travaille avec ses fournisseurs pour assurer la conformité des articles importés ou fabriqués dans l'Union européenne qui sont soumis au règlement REACH (CE-No 1907/2006), Article 33, et utilisés dans la production de ses produits.

En ce qui concerne l'application de l'article 33 du règlement REACH et la publication de la liste des substances extrêmement préoccupantes (SVHC) conformément à l'article 59 du règlement REACH, GE Healthcare est consciente de ses obligations légales et s'y conformera.

Les articles GE Healthcare ne libèrent pas intentionnellement des substances dans des conditions normales d'utilisation.

Selon les informations dont disposent nos fournisseurs à ce jour, ces substances sont présentes dans les produits suivants à une concentration supérieure au seuil de 0,1% masse à masse au niveau de l'article :

Nom du produit	Nom de la substance	n° CAS
XR240amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Cadmium oxide (CdO)	1306-19-0
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro- 1,4,4a,5,6,6a,7,10,10a,11,12,12a- dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5- methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5- tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro- 1,3-dioxo-	552-30-7
	Lead	7439-92-1
Cadmium	7440-43-9	
XR220amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8



	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro-1,4,4a,5,6,6a,7,10,10a,11,12,12a-dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5-methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5-tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro-1,3-dioxo-	552-30-7
	Lead	7439-92-1
	Cadmium	7440-43-9
XR200amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro-1,4,4a,5,6,6a,7,10,10a,11,12,12a-dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5-methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5-tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro-1,3-dioxo-	552-30-7
	Lead	7439-92-1
	Cadmium	7440-43-9
Brivo XR285	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro-1,4,4a,5,6,6a,7,10,10a,11,12,12a-dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5-methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5-tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro-1,3-dioxo-	552-30-7
	Lead	7439-92-1



	Cadmium	7440-43-9
AMX 4/4+/700	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8
Discovery XR656	Lead	7439-92-1
	1,3-Isobenzofurandione, hexahydromethyl-	25550-51-0
	Boron oxide (B2O3)	1303-86-2
	Lead titanium zirconium oxide (Pb(Ti,Zr)O3)	12626-81-2
Optima XR646	Silicic acid, lead salt	11120-22-2
	Lead oxide (PbO)	1317-36-8
	Boron oxide (B2O3)	1303-86-2
	Lead titanium zirconium oxide (Pb(Ti,Zr)O3)	12626-81-2
	Lead	7439-92-1
	1,3-Isobenzofurandione, hexahydromethyl-	25550-51-0
Brivo XR575	1,3-Isobenzofurandione, hexahydro-5-methyl-	19438-60-9
	Silicic acid, lead salt	11120-22-2
Proteus XR/a	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead	7439-92-1
XR6000	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
Brivo XR118	Silicic acid, lead salt	11120-22-2
WDR1	Silicic acid, lead salt	11120-22-2
	Lead	7439-92-1



## GE Healthcare

**Surya Kunduri**  
 REACH Regulations Leader  
 Product Compliance Engineering  
 Suryadutt.Kunduri@ge.com  
 M +33 664083106

**Yachun Du**  
 Senior Architect  
 GEHC X Ray Engineering  
 Yachun.du@ge.com  
 M +86 10 57083340

GE Healthcare работи със своите доставчици, за да осигури съответствие на артикулите, внесени или произведени в рамките на Европейския съюз, които са в обхвата на Регламента REACH (ЕО – № 1907/2006), член 33, и които се използват в производството на продуктите на GE Healthcare. По отношение на прилагането на член 33 на Регламента REACH и публикуването на списъка с предложения за пораждащи сериозно безпокойство вещества (SVHC) съгласно член 59 на Регламента REACH GE Healthcare е осведомена относно своите правни задължения и ще ги спази. Артикулите на GE Healthcare не „отделят умишлено“ вещества при нормални условия на употреба.

Въз основа на информацията от нашите доставчици към днешна дата тези вещества са налични в следните продукти при концентрация, по-голяма от прага от 0,1% обемни процента, при ниво на артикул:

Име на продукт	Наименование на веществото	CAS №
XR240amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Cadmium oxide (CdO)	1306-19-0
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro-1,4,4a,5,6,6a,7,10,10a,11,12,12a-dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5-methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5-tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro-1,3-dioxo-	552-30-7
	Lead	7439-92-1
Cadmium	7440-43-9	
XR220amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8





	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro- 1,4,4a,5,6,6a,7,10,10a,11,12,12a- dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5- methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5- tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro- 1,3-dioxo-	552-30-7
	Lead	7439-92-1
	Cadmium	7440-43-9
XR200amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro- 1,4,4a,5,6,6a,7,10,10a,11,12,12a- dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5- methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5- tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro- 1,3-dioxo-	552-30-7
	Lead	7439-92-1
	Cadmium	7440-43-9
Brivo XR285	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro- 1,4,4a,5,6,6a,7,10,10a,11,12,12a- dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5- methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5- tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro- 1,3-dioxo-	552-30-7
	Lead	7439-92-1



	Cadmium	7440-43-9
AMX 4/4+/700	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8
Discovery XR656	Lead	7439-92-1
	1,3-Isobenzofurandione, hexahydromethyl-	25550-51-0
	Boron oxide (B2O3)	1303-86-2
	Lead titanium zirconium oxide (Pb(Ti,Zr)O3)	12626-81-2
Optima XR646	Silicic acid, lead salt	11120-22-2
	Lead oxide (PbO)	1317-36-8
	Boron oxide (B2O3)	1303-86-2
	Lead titanium zirconium oxide (Pb(Ti,Zr)O3)	12626-81-2
	Lead	7439-92-1
	1,3-Isobenzofurandione, hexahydromethyl-	25550-51-0
Brivo XR575	1,3-Isobenzofurandione, hexahydro-5-methyl-	19438-60-9
	Silicic acid, lead salt	11120-22-2
Proteus XR/a	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead	7439-92-1
XR6000	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
Brivo XR118	Silicic acid, lead salt	11120-22-2
WDR1	Silicic acid, lead salt	11120-22-2
	Lead	7439-92-1



GE Healthcare

**Surya Kunduri**  
REACH Regulations Leader  
Product Compliance Engineering  
Suryadutt.Kunduri@ge.com  
M +33 664083106

**Yachun Du**  
Senior Architect  
GEHC X Ray Engineering  
Yachun.du@ge.com  
M +86 10 57083340

Společnost GE Healthcare spolupracuje se svými dodavateli na zajištění souladu výrobků dovážených nebo vyrobených v Evropské unii, které podléhají směrnici REACH (EC- č. 1907/2006), článek 33, a použitých při výrobě produktů GE Healthcare.

Pokud jde o aplikaci článku 33 nařízení REACH a publikaci Candidate List of Substances of Very High Concern (SVHC) (Seznam navržených látek vzbuzujících mimořádné obavy) podle článku 59 směrnice REACH, společnost GE Healthcare si je vědoma zákonných závazků a bude je dodržovat.

Výrobky společnosti GE Healthcare za normálních podmínek „záměrně neuvolňují“ tyto látky.

Na základě aktuálních informací od našich dodavatelů jsou tyto látky přítomny v následujících produktech v koncentraci vyšší než 0,1 % hmotnosti na úrovni výrobku:

Název produktu	Název látky	Č. CAS
XR240amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Cadmium oxide (CdO)	1306-19-0
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro- 1,4,4a,5,6,6a,7,10,10a,11,12,12a- dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5- methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5- tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro- 1,3-dioxo-	552-30-7
	Lead	7439-92-1
Cadmium	7440-43-9	
XR220amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8



	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro- 1,4,4a,5,6,6a,7,10,10a,11,12,12a- dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5- methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5- tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro- 1,3-dioxo-	552-30-7
	Lead	7439-92-1
	Cadmium	7440-43-9
XR200amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro- 1,4,4a,5,6,6a,7,10,10a,11,12,12a- dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5- methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5- tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro- 1,3-dioxo-	552-30-7
	Lead	7439-92-1
	Cadmium	7440-43-9
Brivo XR285	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro- 1,4,4a,5,6,6a,7,10,10a,11,12,12a- dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5- methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5- tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro- 1,3-dioxo-	552-30-7
	Lead	7439-92-1



	Cadmium	7440-43-9
AMX 4/4+/700	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8
Discovery XR656	Lead	7439-92-1
	1,3-Isobenzofurandione, hexahydromethyl-	25550-51-0
	Boron oxide (B2O3)	1303-86-2
	Lead titanium zirconium oxide (Pb(Ti,Zr)O3)	12626-81-2
Optima XR646	Silicic acid, lead salt	11120-22-2
	Lead oxide (PbO)	1317-36-8
	Boron oxide (B2O3)	1303-86-2
	Lead titanium zirconium oxide (Pb(Ti,Zr)O3)	12626-81-2
	Lead	7439-92-1
	1,3-Isobenzofurandione, hexahydromethyl-	25550-51-0
Brivo XR575	1,3-Isobenzofurandione, hexahydro-5-methyl-	19438-60-9
	Silicic acid, lead salt	11120-22-2
Proteus XR/a	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead	7439-92-1
XR6000	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
Brivo XR118	Silicic acid, lead salt	11120-22-2
WDR1	Silicic acid, lead salt	11120-22-2
	Lead	7439-92-1



## GE Healthcare

**Surya Kunduri**  
 REACH Regulations Leader  
 Product Compliance Engineering  
 Suryadutt.Kunduri@ge.com  
 M +33 664083106

**Yachun Du**  
 Senior Architect  
 GEHC X Ray Engineering  
 Yachun.du@ge.com  
 M +86 10 57083340

GE Healthcare trabaja con sus proveedores para garantizar el cumplimiento del reglamento REACH (CE n.º 1907/2006), artículo 33, en artículos importados o fabricados dentro de la Unión Europea sujetos a dicho reglamento y que se utilicen en la producción de productos de GE Healthcare.

En relación con la aplicación del artículo 33 del reglamento REACH y la publicación de la lista de sustancias candidatas extremadamente preocupantes (SEP) de acuerdo con el artículo 59 del reglamento REACH, GE Healthcare está al tanto de sus obligaciones legales y las cumple.

Los artículos de GE Healthcare no "liberan intencionalmente" sustancias en condiciones normales de uso.

Sobre la base de la información de nuestros proveedores hasta la fecha, estas sustancias están presentes en los siguientes productos con una concentración mayor que el umbral del 0,1 % en peso a nivel del artículo:

Nombre del producto	Nombre de la sustancia	número CAS.
XR240amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Cadmium oxide (CdO)	1306-19-0
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro-1,4,4a,5,6,6a,7,10,10a,11,12,12a-dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5-methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5-tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro-1,3-dioxo-	552-30-7
	Lead	7439-92-1
Cadmium	7440-43-9	
XR220amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8



	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro-1,4,4a,5,6,6a,7,10,10a,11,12,12a-dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5-methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5-tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro-1,3-dioxo-	552-30-7
	Lead	7439-92-1
	Cadmium	7440-43-9
XR200amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro-1,4,4a,5,6,6a,7,10,10a,11,12,12a-dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5-methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5-tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro-1,3-dioxo-	552-30-7
	Lead	7439-92-1
Cadmium	7440-43-9	
Brivo XR285	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro-1,4,4a,5,6,6a,7,10,10a,11,12,12a-dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5-methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5-tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro-1,3-dioxo-	552-30-7
	Lead	7439-92-1



	Cadmium	7440-43-9
AMX 4/4+/700	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8
Discovery XR656	Lead	7439-92-1
	1,3-Isobenzofurandione, hexahydromethyl-	25550-51-0
	Boron oxide (B2O3)	1303-86-2
	Lead titanium zirconium oxide (Pb(Ti,Zr)O3)	12626-81-2
Optima XR646	Silicic acid, lead salt	11120-22-2
	Lead oxide (PbO)	1317-36-8
	Boron oxide (B2O3)	1303-86-2
	Lead titanium zirconium oxide (Pb(Ti,Zr)O3)	12626-81-2
	Silicic acid, lead salt	11120-22-2
	Lead	7439-92-1
Brivo XR575	1,3-Isobenzofurandione, hexahydromethyl-	25550-51-0
	1,3-Isobenzofurandione, hexahydro-5-methyl-	19438-60-9
Proteus XR/a	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead	7439-92-1
XR6000	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
Brivo XR118	Silicic acid, lead salt	11120-22-2
WDR1	Silicic acid, lead salt	11120-22-2
	Lead	7439-92-1





## GE Healthcare

**Surya Kunduri**  
REACH Regulations Leader  
Product Compliance Engineering  
Suryadutt.Kunduri@ge.com  
M +33 664083106

**Yachun Du**  
Senior Architect  
GEHC X Ray Engineering  
Yachun.du@ge.com  
M +86 10 57083340

GE Healthcare samarbejder med sine leverandører for at sikre overensstemmelse af artikler, der er importeret eller fremstillet inden for EU, som er underlagt REACH-forordningen (EF nr. 1907/2006), artikel 33, og som anvendes i produktionen af GE Healthcare-produkter.

Med hensyn til anvendelsen af artikel 33 i REACH-forordningen og offentliggørelsen af kandidatlisten over særligt farlige stoffer (SVHC) i henhold til artikel 59 i REACH-forordningen er GE Healthcare bekendt med sine juridiske forpligtelser og vil overholde dem.

GE Healthcare-artikler "frigiver ikke tilsigtet" stoffer under normale brugsforhold.

På baggrund af oplysninger fra vores leverandører til dato findes disse stoffer i følgende produkter ved en koncentration, der er større end grænseværdien på 0,1 vægtprocent på artikelniveau:

Produktnavn	Stofnavn	CAS-nr.
XR240amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Cadmium oxide (CdO)	1306-19-0
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro- 1,4,4a,5,6,6a,7,10,10a,11,12,12a- dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5- methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5- tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro- 1,3-dioxo-	552-30-7
Lead	7439-92-1	
Cadmium	7440-43-9	
XR220amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro- 1,4,4a,5,6,6a,7,10,10a,11,12,12a- dodecahydro-	13560-89-9



	1,3-Isobenzofurandione, hexahydro-5-methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5-tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro-1,3-dioxo-	552-30-7
	Lead	7439-92-1
	Cadmium	7440-43-9
XR200amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro-1,4,4a,5,6,6a,7,10,10a,11,12,12a-dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5-methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5-tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro-1,3-dioxo-	552-30-7
	Lead	7439-92-1
Cadmium	7440-43-9	
Brivo XR285	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro-1,4,4a,5,6,6a,7,10,10a,11,12,12a-dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5-methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5-tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro-1,3-dioxo-	552-30-7
	Lead	7439-92-1
Cadmium	7440-43-9	
AMX 4/4+/700	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2



	Lead oxide (PbO)	1317-36-8
Discovery XR656	Lead 1,3-Isobenzofurandione, hexahydromethyl- Boron oxide (B2O3) Lead titanium zirconium oxide (Pb(Ti,Zr)O3) Silicic acid, lead salt	7439-92-1 25550-51-0 1303-86-2 12626-81-2 11120-22-2
Optima XR646	Lead oxide (PbO) Boron oxide (B2O3) Lead titanium zirconium oxide (Pb(Ti,Zr)O3) Silicic acid, lead salt Lead 1,3-Isobenzofurandione, hexahydromethyl- 1,3-Isobenzofurandione, hexahydro-5- methyl-	1317-36-8 1303-86-2 12626-81-2 11120-22-2 7439-92-1 25550-51-0 19438-60-9
Brivo XR575	Silicic acid, lead salt	11120-22-2
Proteus XR/a	Silicic acid, lead salt Boron oxide (B2O3) Lead	11120-22-2 1303-86-2 7439-92-1
XR6000	Silicic acid, lead salt Boron oxide (B2O3)	11120-22-2 1303-86-2
Brivo XR118	Silicic acid, lead salt	11120-22-2
WDR1	Silicic acid, lead salt Lead	11120-22-2 7439-92-1



## GE Healthcare

**Surya Kunduri**  
 REACH Regulations Leader  
 Product Compliance Engineering  
 Suryadutt.Kunduri@ge.com  
 M +33 664083106

**Yachun Du**  
 Senior Architect  
 GEHC X Ray Engineering  
 Yachun.du@ge.com  
 M +86 10 57083340

GE Healthcare arbeitet mit seinen Lieferanten zusammen, um die Konformität von Artikeln sicherzustellen, die in die Europäische Union eingeführt oder dort hergestellt werden, die der REACH-Verordnung (EG-Nr. 1907/2006), Artikel 33, unterliegen und die bei der Herstellung von GE Healthcare-Produkten verwendet werden.

Hinsichtlich der Anwendung von Artikel 33 der REACH-Verordnung und der Veröffentlichung der Kandidatenliste für besonders besorgniserregende Stoffe (SVHC-Liste) gemäß Artikel 59 der REACH-Verordnung ist GE Healthcare sich seiner rechtlichen Verpflichtungen bewusst und wird diese einhalten.

Artikel von GE Healthcare geben unter normalen Nutzungsbedingungen keine Stoffe „absichtlich frei“. Basierend auf Informationen unserer jetzigen Lieferanten sind diese Stoffe in den folgenden Produkten mit einer höheren Konzentration als dem Schwellenwert von 0,1 % des Artikelgewichts vorhanden:

Produktname	Stoffname	CAS-Nr.
XR240amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Cadmium oxide (CdO)	1306-19-0
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene,	13560-89-9
	1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro-	
	1,4,4a,5,6,6a,7,10,10a,11,12,12a-	
	dodecahydro-	
	1,3-Isobenzofurandione, hexahydro-5-	19438-60-9
	methyl-	
1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5-	2451-62-9	
tris(2-oxiranylmethyl)-		
Formaldehyde	50-00-0	
5-Isobenzofurancarboxylic acid, 1,3-dihydro-	552-30-7	
1,3-dioxo-		
Lead	7439-92-1	
Cadmium	7440-43-9	
XR220amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8



	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro- 1,4,4a,5,6,6a,7,10,10a,11,12,12a- dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5- methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5- tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro- 1,3-dioxo-	552-30-7
	Lead	7439-92-1
	Cadmium	7440-43-9
XR200amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro- 1,4,4a,5,6,6a,7,10,10a,11,12,12a- dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5- methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5- tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro- 1,3-dioxo-	552-30-7
	Lead	7439-92-1
	Cadmium	7440-43-9
Brivo XR285	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro- 1,4,4a,5,6,6a,7,10,10a,11,12,12a- dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5- methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5- tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro- 1,3-dioxo-	552-30-7
	Lead	7439-92-1



	Cadmium	7440-43-9
AMX 4/4+/700	Silicic acid, lead salt Boron oxide (B <sub>2</sub> O <sub>3</sub> ) Lead oxide (PbO)	11120-22-2 1303-86-2 1317-36-8
Discovery XR656	Lead 1,3-Isobenzofurandione, hexahydromethyl- Boron oxide (B <sub>2</sub> O <sub>3</sub> ) Lead titanium zirconium oxide (Pb(Ti,Zr)O <sub>3</sub> ) Silicic acid, lead salt	7439-92-1 25550-51-0 1303-86-2 12626-81-2 11120-22-2
Optima XR646	Lead oxide (PbO) Boron oxide (B <sub>2</sub> O <sub>3</sub> ) Lead titanium zirconium oxide (Pb(Ti,Zr)O <sub>3</sub> ) Silicic acid, lead salt Lead 1,3-Isobenzofurandione, hexahydromethyl- 1,3-Isobenzofurandione, hexahydro-5- methyl-	1317-36-8 1303-86-2 12626-81-2 11120-22-2 7439-92-1 25550-51-0 19438-60-9
Brivo XR575	Silicic acid, lead salt	11120-22-2
Proteus XR/a	Silicic acid, lead salt Boron oxide (B <sub>2</sub> O <sub>3</sub> ) Lead	11120-22-2 1303-86-2 7439-92-1
XR6000	Silicic acid, lead salt Boron oxide (B <sub>2</sub> O <sub>3</sub> )	11120-22-2 1303-86-2
Brivo XR118	Silicic acid, lead salt	11120-22-2
WDR1	Silicic acid, lead salt Lead	11120-22-2 7439-92-1



## GE Healthcare

**Surya Kunduri**  
REACH Regulations Leader  
Product Compliance Engineering  
Suryadutt.Kunduri@ge.com  
M +33 664083106

**Yachun Du**  
Senior Architect  
GEHC X Ray Engineering  
Yachun.du@ge.com  
M +86 10 57083340

GE Healthcare teeb oma tarnijatega koostööd, et tagada nende Euroopa Liidus imporditud või toodetud toodete vastavus, millele kohaldub REACH-määruse ((EÜ) nr 1907/2006) artikkel 33 ning mida kasutatakse GE Healthcare'i toodete tootmisel.

Seoses REACH-määruse artikli 33 kohaldamise ja väga ohtlike ainete kandidaatainete nimekirja (SVHC) avaldamisega REACH-määruse artikli 59 kohaselt on GE Healthcare oma juriidilistest kohustustest teadlik ning täidab neid.

GE Healthcare'i toodetest ei ole tavalistes kasutustingimustes ainete „eraldumine ette nähtud“.

Tarnijatelt saadud teabe kohaselt on need ained järgmistes toodetes olemas sisalduses, mis on toote tasemel suurem kui piirväärtus 0,1 massiprotsenti:

Toote nimetus	Aine nimetus	CASi nr
XR240amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Cadmium oxide (CdO)	1306-19-0
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro-1,4,4a,5,6,6a,7,10,10a,11,12,12a-dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5-methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5-tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro-1,3-dioxo-	552-30-7
Lead	7439-92-1	
Cadmium	7440-43-9	
XR220amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro-1,4,4a,5,6,6a,7,10,10a,11,12,12a-dodecahydro-	13560-89-9



	1,3-Isobenzofurandione, hexahydro-5-methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5-tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro-1,3-dioxo-	552-30-7
	Lead	7439-92-1
	Cadmium	7440-43-9
XR200amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro-1,4,4a,5,6,6a,7,10,10a,11,12,12a-dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5-methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5-tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro-1,3-dioxo-	552-30-7
	Lead	7439-92-1
	Cadmium	7440-43-9
Brivo XR285	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro-1,4,4a,5,6,6a,7,10,10a,11,12,12a-dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5-methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5-tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro-1,3-dioxo-	552-30-7
	Lead	7439-92-1
	Cadmium	7440-43-9
AMX 4/4+/700	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2





	Lead oxide (PbO)	1317-36-8
Discovery XR656	Lead 1,3-Isobenzofurandione, hexahydromethyl- Boron oxide (B2O3) Lead titanium zirconium oxide (Pb(Ti,Zr)O3) Silicic acid, lead salt	7439-92-1 25550-51-0 1303-86-2 12626-81-2 11120-22-2
Optima XR646	Lead oxide (PbO) Boron oxide (B2O3) Lead titanium zirconium oxide (Pb(Ti,Zr)O3) Silicic acid, lead salt Lead 1,3-Isobenzofurandione, hexahydromethyl- 1,3-Isobenzofurandione, hexahydro-5- methyl-	1317-36-8 1303-86-2 12626-81-2 11120-22-2 7439-92-1 25550-51-0 19438-60-9
Brivo XR575	Silicic acid, lead salt	11120-22-2
Proteus XR/a	Silicic acid, lead salt Boron oxide (B2O3) Lead	11120-22-2 1303-86-2 7439-92-1
XR6000	Silicic acid, lead salt Boron oxide (B2O3)	11120-22-2 1303-86-2
Brivo XR118	Silicic acid, lead salt	11120-22-2
WDR1	Silicic acid, lead salt Lead	11120-22-2 7439-92-1



## GE Healthcare

**Surya Kunduri**  
REACH Regulations Leader  
Product Compliance Engineering  
Suryadutt.Kunduri@ge.com  
M +33 664083106

**Yachun Du**  
Senior Architect  
GEHC X Ray Engineering  
Yachun.du@ge.com  
M +86 10 57083340

Η GE Healthcare συνεργάζεται με τους προμηθευτές της για τη διασφάλιση της συμμόρφωσης των αντικειμένων που εισάγονται ή κατασκευάζονται εντός της Ευρωπαϊκής Ένωσης, υπόκεινται στον κανονισμό REACH (ΕΚ- Αρ. 1907/2006), Άρθρο 33 και χρησιμοποιούνται για την παραγωγή των προϊόντων της GE Healthcare.

Αναφορικά με την εφαρμογή του Άρθρου 33 του κανονισμού REACH και τη δημοσίευση του Καταλόγου υποψήφιων ουσιών που προκαλούν πολύ μεγάλη ανησυχία (Candidate List of Substances of Very High Concern, SVHC) σύμφωνα με το Άρθρο 59 του κανονισμού REACH, η GE Healthcare έχει λάβει γνώση των νομίμων υποχρεώσεών της και θα συμμορφώνεται με αυτές.

Τα αντικείμενα της GE Healthcare δεν "απελευθερώνουν εκουσίως" ουσίες υπό κανονικές συνθήκες χρήσης.

Βάσει πληροφοριών από τους προμηθευτές μας έως σήμερα, αυτές οι ουσίες υπάρχουν στα παρακάτω προϊόντα σε ποσοστό συγκέντρωσης μεγαλύτερο από το όριο του 0,1% βάρος προς βάρος σε επίπεδο αντικειμένου:

Όνομα προϊόντος	Όνομασία ουσίας	Αριθμός CAS
XR240amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Cadmium oxide (CdO)	1306-19-0
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene,	13560-89-9
	1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro-	
	1,4,4a,5,6,6a,7,10,10a,11,12,12a-	
	dodecahydro-	
	1,3-Isobenzofurandione, hexahydro-5-	19438-60-9
	methyl-	
1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5-	2451-62-9	
tris(2-oxiranylmethyl)-		
Formaldehyde	50-00-0	
5-Isobenzofurancarboxylic acid, 1,3-dihydro-	552-30-7	
1,3-dioxo-		
Lead	7439-92-1	
Cadmium	7440-43-9	
XR220amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2



	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro-1,4,4a,5,6,6a,7,10,10a,11,12,12a-dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5-methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5-tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro-1,3-dioxo-	552-30-7
	Lead	7439-92-1
	Cadmium	7440-43-9
XR200amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro-1,4,4a,5,6,6a,7,10,10a,11,12,12a-dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5-methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5-tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro-1,3-dioxo-	552-30-7
	Lead	7439-92-1
	Cadmium	7440-43-9
Brivo XR285	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro-1,4,4a,5,6,6a,7,10,10a,11,12,12a-dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5-methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5-tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro-1,3-dioxo-	552-30-7



	Lead	7439-92-1
	Cadmium	7440-43-9
AMX 4/4+/700	Silicic acid, lead salt	11120-22-2
	Boron oxide (B <sub>2</sub> O <sub>3</sub> )	1303-86-2
	Lead oxide (PbO)	1317-36-8
Discovery XR656	Lead	7439-92-1
	1,3-Isobenzofurandione, hexahydromethyl-	25550-51-0
	Boron oxide (B <sub>2</sub> O <sub>3</sub> )	1303-86-2
	Lead titanium zirconium oxide (Pb(Ti,Zr)O <sub>3</sub> )	12626-81-2
	Silicic acid, lead salt	11120-22-2
Optima XR646	Lead oxide (PbO)	1317-36-8
	Boron oxide (B <sub>2</sub> O <sub>3</sub> )	1303-86-2
	Lead titanium zirconium oxide (Pb(Ti,Zr)O <sub>3</sub> )	12626-81-2
	Silicic acid, lead salt	11120-22-2
	Lead	7439-92-1
	1,3-Isobenzofurandione, hexahydromethyl-	25550-51-0
	1,3-Isobenzofurandione, hexahydro-5-methyl-	19438-60-9
Brivo XR575	Silicic acid, lead salt	11120-22-2
Proteus XR/a	Silicic acid, lead salt	11120-22-2
	Boron oxide (B <sub>2</sub> O <sub>3</sub> )	1303-86-2
	Lead	7439-92-1
XR6000	Silicic acid, lead salt	11120-22-2
	Boron oxide (B <sub>2</sub> O <sub>3</sub> )	1303-86-2
Brivo XR118	Silicic acid, lead salt	11120-22-2
WDR1	Silicic acid, lead salt	11120-22-2
	Lead	7439-92-1



## GE Healthcare

**Surya Kunduri**  
REACH Regulations Leader  
Product Compliance Engineering  
Suryadutt.Kunduri@ge.com  
M +33 664083106

**Yachun Du**  
Senior Architect  
GEHC X Ray Engineering  
Yachun.du@ge.com  
M +86 10 57083340

GE Healthcare surađuje s dobavljačima kako bi osigurao sukladnost proizvoda uvezenih ili proizvedenih u Europskoj uniji koji su podložni uredbi REACH (EZ – br. 1907/2006), Članak 33, a koriste se u proizvodnji proizvoda tvrtke GE Healthcare.

Vezano uz primjenu Članka 33 uredbe REACH i objave Popisa predloženih posebno zabrinjavajućih tvari za odobrenje (SVHC) sukladno Članku 59 uredbe REACH, GE Healthcare je upoznat sa svojim pravnim obavezama i ispoštovat će ih.

Proizvodi tvrtke GE Healthcare prilikom uobičajene uporabe tvari ne „ispuštaju namjerno“.

Na temelju podataka do sad dobivenih od naših dobavljača, ove su tvari prisutne u sljedećim proizvodima u koncentracijama većima od praga od 0,1 % masenog udjela na razini proizvoda:

Naziv proizvoda	Naziv tvari	CAS broj
XR240amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Cadmium oxide (CdO)	1306-19-0
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro-1,4,4a,5,6,6a,7,10,10a,11,12,12a-dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5-methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5-tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro-1,3-dioxo-	552-30-7
	Lead	7439-92-1
Cadmium	7440-43-9	
XR220amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro-1,4,4a,5,6,6a,7,10,10a,11,12,12a-dodecahydro-	13560-89-9



	1,3-Isobenzofurandione, hexahydro-5-methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5-tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro-1,3-dioxo-	552-30-7
	Lead	7439-92-1
	Cadmium	7440-43-9
XR200amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro-1,4,4a,5,6,6a,7,10,10a,11,12,12a-dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5-methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5-tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro-1,3-dioxo-	552-30-7
	Lead	7439-92-1
	Cadmium	7440-43-9
Brivo XR285	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro-1,4,4a,5,6,6a,7,10,10a,11,12,12a-dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5-methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5-tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro-1,3-dioxo-	552-30-7
	Lead	7439-92-1
	Cadmium	7440-43-9
AMX 4/4+/700	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2



	Lead oxide (PbO)	1317-36-8
Discovery XR656	Lead 1,3-Isobenzofurandione, hexahydromethyl- Boron oxide (B2O3) Lead titanium zirconium oxide (Pb(Ti,Zr)O3) Silicic acid, lead salt	7439-92-1 25550-51-0 1303-86-2 12626-81-2 11120-22-2
Optima XR646	Lead oxide (PbO) Boron oxide (B2O3) Lead titanium zirconium oxide (Pb(Ti,Zr)O3) Silicic acid, lead salt Lead 1,3-Isobenzofurandione, hexahydromethyl- 1,3-Isobenzofurandione, hexahydro-5-methyl-	1317-36-8 1303-86-2 12626-81-2 11120-22-2 7439-92-1 25550-51-0 19438-60-9
Brivo XR575	Silicic acid, lead salt	11120-22-2
Proteus XR/a	Silicic acid, lead salt Boron oxide (B2O3) Lead	11120-22-2 1303-86-2 7439-92-1
XR6000	Silicic acid, lead salt Boron oxide (B2O3)	11120-22-2 1303-86-2
Brivo XR118	Silicic acid, lead salt	11120-22-2
WDR1	Silicic acid, lead salt Lead	11120-22-2 7439-92-1



## GE Healthcare

**Surya Kunduri**  
 REACH Regulations Leader  
 Product Compliance Engineering  
 Suryadutt.Kunduri@ge.com  
 M +33 664083106

**Yachun Du**  
 Senior Architect  
 GEHC X Ray Engineering  
 Yachun.du@ge.com  
 M +86 10 57083340

GE Healthcare collabora con i suoi fornitori per garantire la conformità degli articoli importati o prodotti nell'Unione Europea soggetti al regolamento REACH (CE N. 1907/2006), articolo 33, e utilizzati nella fabbricazione di prodotti GE Healthcare.

Per quanto riguarda l'applicazione dell'articolo 33 del regolamento REACH e la pubblicazione dell'elenco delle sostanze candidate estremamente preoccupanti (SVHC, Substances of Very High Concern) in conformità all'articolo 59 del regolamento REACH, GE Healthcare è a conoscenza dei suoi obblighi legali e si impegna a rispettarli.

Gli articoli GE Healthcare non "rilasciano intenzionalmente" sostanze in condizioni di normale utilizzo. In base alle informazioni aggiornate ad oggi ottenute dai nostri fornitori, queste sostanze sono presenti nei seguenti prodotti in una concentrazione superiore alla soglia dello 0,1% in peso/peso a livello di articolo:

Nome prodotto	Denominazione della sostanza	N. CAS
XR240amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B <sub>2</sub> O <sub>3</sub> )	1303-86-2
	Cadmium oxide (CdO)	1306-19-0
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro-1,4,4a,5,6,6a,7,10,10a,11,12,12a-dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5-methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5-tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehide	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro-1,3-dioxo-	552-30-7
	Lead	7439-92-1
Cadmium	7440-43-9	
XR220amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B <sub>2</sub> O <sub>3</sub> )	1303-86-2
	Lead oxide (PbO)	1317-36-8





	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro- 1,4,4a,5,6,6a,7,10,10a,11,12,12a- dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5- methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5- tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro- 1,3-dioxo-	552-30-7
	Lead	7439-92-1
	Cadmium	7440-43-9
XR200amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro- 1,4,4a,5,6,6a,7,10,10a,11,12,12a- dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5- methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5- tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro- 1,3-dioxo-	552-30-7
	Lead	7439-92-1
	Cadmium	7440-43-9
Brivo XR285	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro- 1,4,4a,5,6,6a,7,10,10a,11,12,12a- dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5- methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5- tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro- 1,3-dioxo-	552-30-7
	Lead	7439-92-1



	Cadmium	7440-43-9
AMX 4/4+/700	Silicic acid, lead salt Boron oxide (B <sub>2</sub> O <sub>3</sub> ) Lead oxide (PbO)	11120-22-2 1303-86-2 1317-36-8
Discovery XR656	Lead 1,3-Isobenzofurandione, hexahydromethyl- Boron oxide (B <sub>2</sub> O <sub>3</sub> ) Lead titanium zirconium oxide (Pb(Ti,Zr)O <sub>3</sub> ) Silicic acid, lead salt	7439-92-1 25550-51-0 1303-86-2 12626-81-2 11120-22-2
Optima XR646	Lead oxide (PbO) Boron oxide (B <sub>2</sub> O <sub>3</sub> ) Lead titanium zirconium oxide (Pb(Ti,Zr)O <sub>3</sub> ) Silicic acid, lead salt Lead 1,3-Isobenzofurandione, hexahydromethyl- 1,3-Isobenzofurandione, hexahydro-5- methyl-	1317-36-8 1303-86-2 12626-81-2 11120-22-2 7439-92-1 25550-51-0 19438-60-9
Brivo XR575	Silicic acid, lead salt	11120-22-2
Proteus XR/a	Silicic acid, lead salt Boron oxide (B <sub>2</sub> O <sub>3</sub> ) Lead	11120-22-2 1303-86-2 7439-92-1
XR6000	Silicic acid, lead salt Boron oxide (B <sub>2</sub> O <sub>3</sub> )	11120-22-2 1303-86-2
Brivo XR118	Silicic acid, lead salt	11120-22-2
WDR1	Silicic acid, lead salt Lead	11120-22-2 7439-92-1



## GE Healthcare

**Surya Kunduri**  
REACH Regulations Leader  
Product Compliance Engineering  
Suryadutt.Kunduri@ge.com  
M +33 664083106

**Yachun Du**  
Senior Architect  
GEHC X Ray Engineering  
Yachun.du@ge.com  
M +86 10 57083340

GE Healthcare sadarbojas ar saviem piegādātājiem, lai nodrošinātu atbilstību Eiropas Savienībā importētajām vai ražotajām precēm, uz kurām attiecas REACH regulas (EK Nr. 1907/2006) 33. pants un kas tiek izmantotas GE Healthcare produktu ražošanā.

Attiecībā uz REACH regulas 33. panta pielietojumu un kandidātvielu, kas rada ļoti lielas bažas (SVHC), publikāciju saskaņā ar REACH regulas 59. pantu GE Healthcare apzinās savas likumīgās saistības un tās ievēros.

GE Healthcare preces normālos lietošanas apstākļos “tīši neizdala” vielas.

Pamatojoties uz līdzšinējo informāciju no mūsu piegādātājiem, šīs vielas turpmāk minētajos produktos ir koncentrācijā, kas pārsniedz 0,1 % svara robežvērtību pēc svara preces līmenī:

Izstrādājuma nosaukums	Vielas	CAS Nr.
XR240amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B <sub>2</sub> O <sub>3</sub> )	1303-86-2
	Cadmium oxide (CdO)	1306-19-0
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene,	13560-89-9
	1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro-	
	1,4,4a,5,6,6a,7,10,10a,11,12,12a-	
	dodecahydro-	
	1,3-Isobenzofurandione, hexahydro-5-	19438-60-9
	methyl-	
1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5-	2451-62-9	
tris(2-oxiranylmethyl)-		
Formaldehyde	50-00-0	
5-Isobenzofurancarboxylic acid, 1,3-dihydro-	552-30-7	
1,3-dioxo-		
Lead	7439-92-1	
Cadmium	7440-43-9	
XR220amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B <sub>2</sub> O <sub>3</sub> )	1303-86-2
	Lead oxide (PbO)	1317-36-8



	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro- 1,4,4a,5,6,6a,7,10,10a,11,12,12a- dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5- methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5- tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro- 1,3-dioxo-	552-30-7
	Lead	7439-92-1
	Cadmium	7440-43-9
XR200amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro- 1,4,4a,5,6,6a,7,10,10a,11,12,12a- dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5- methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5- tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro- 1,3-dioxo-	552-30-7
	Lead	7439-92-1
	Cadmium	7440-43-9
Brivo XR285	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro- 1,4,4a,5,6,6a,7,10,10a,11,12,12a- dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5- methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5- tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro- 1,3-dioxo-	552-30-7
	Lead	7439-92-1



	Cadmium	7440-43-9
AMX 4/4+/700	Silicic acid, lead salt Boron oxide (B <sub>2</sub> O <sub>3</sub> ) Lead oxide (PbO)	11120-22-2 1303-86-2 1317-36-8
Discovery XR656	Lead 1,3-Isobenzofurandione, hexahydromethyl- Boron oxide (B <sub>2</sub> O <sub>3</sub> ) Lead titanium zirconium oxide (Pb(Ti,Zr)O <sub>3</sub> ) Silicic acid, lead salt	7439-92-1 25550-51-0 1303-86-2 12626-81-2 11120-22-2
Optima XR646	Lead oxide (PbO) Boron oxide (B <sub>2</sub> O <sub>3</sub> ) Lead titanium zirconium oxide (Pb(Ti,Zr)O <sub>3</sub> ) Silicic acid, lead salt Lead 1,3-Isobenzofurandione, hexahydromethyl- 1,3-Isobenzofurandione, hexahydro-5- methyl-	1317-36-8 1303-86-2 12626-81-2 11120-22-2 7439-92-1 25550-51-0 19438-60-9
Brivo XR575	Silicic acid, lead salt	11120-22-2
Proteus XR/a	Silicic acid, lead salt Boron oxide (B <sub>2</sub> O <sub>3</sub> ) Lead	11120-22-2 1303-86-2 7439-92-1
XR6000	Silicic acid, lead salt Boron oxide (B <sub>2</sub> O <sub>3</sub> )	11120-22-2 1303-86-2
Brivo XR118	Silicic acid, lead salt	11120-22-2
WDR1	Silicic acid, lead salt Lead	11120-22-2 7439-92-1



## GE Healthcare

**Surya Kunduri**  
REACH Regulations Leader  
Product Compliance Engineering  
Suryadutt.Kunduri@ge.com  
M +33 664083106

**Yachun Du**  
Senior Architect  
GEHC X Ray Engineering  
Yachun.du@ge.com  
M +86 10 57083340

„GE Healthcare“ bendradarbiauja su savo tiekėjais, kad užtikrintų, jog prekės, importuotos arba pagamintos Europos Sąjungoje, atitiktų REACH reglamento (EB Nr. 1907/2006) 33 str. nuostatas, ir yra naudojamos „GE Healthcare“ produktų gamybai.

„GE Healthcare“ supranta savo teisinius įsipareigojimus pagal REACH direktyvos 33 str. ir Labai didelį susirūpinimą keliančių medžiagų kandidatų sąrašą pagal REACH direktyvos 59 str., ir jų laikosi „GE Healthcare“ produktai įprastomis naudojimo sąlygomis „sąmoningai neišskiria“ medžiagų į orą. Remiantis mūsų tiekėjų turima informacija, šios medžiagos toliau išvardintuose produktuose yra didesnės koncentracijos nei ribinė 0,1 % svorio pagal svorį koncentracija prekės lygiu:

Gaminio pavadinimas	Cheminės medžiagos pavadinimas	CAS Nr.
XR240amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Cadmium oxide (CdO)	1306-19-0
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro-1,4,4a,5,6,6a,7,10,10a,11,12,12a-dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5-methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5-tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro-1,3-dioxo-	552-30-7
	Lead	7439-92-1
Cadmium	7440-43-9	
XR220amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro-1,4,4a,5,6,6a,7,10,10a,11,12,12a-dodecahydro-	13560-89-9



	1,3-Isobenzofurandione, hexahydro-5-methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5-tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro-1,3-dioxo-	552-30-7
	Lead	7439-92-1
	Cadmium	7440-43-9
XR200amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro-1,4,4a,5,6,6a,7,10,10a,11,12,12a-dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5-methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5-tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro-1,3-dioxo-	552-30-7
	Lead	7439-92-1
	Cadmium	7440-43-9
Brivo XR285	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro-1,4,4a,5,6,6a,7,10,10a,11,12,12a-dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5-methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5-tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro-1,3-dioxo-	552-30-7
	Lead	7439-92-1
	Cadmium	7440-43-9
AMX 4/4+/700	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2



	Lead oxide (PbO)	1317-36-8
Discovery XR656	Lead 1,3-Isobenzofurandione, hexahydromethyl- Boron oxide (B2O3) Lead titanium zirconium oxide (Pb(Ti,Zr)O3) Silicic acid, lead salt	7439-92-1 25550-51-0 1303-86-2 12626-81-2 11120-22-2
Optima XR646	Lead oxide (PbO) Boron oxide (B2O3) Lead titanium zirconium oxide (Pb(Ti,Zr)O3) Silicic acid, lead salt Lead 1,3-Isobenzofurandione, hexahydromethyl- 1,3-Isobenzofurandione, hexahydro-5- methyl-	1317-36-8 1303-86-2 12626-81-2 11120-22-2 7439-92-1 25550-51-0 19438-60-9
Brivo XR575	Silicic acid, lead salt	11120-22-2
Proteus XR/a	Silicic acid, lead salt Boron oxide (B2O3) Lead	11120-22-2 1303-86-2 7439-92-1
XR6000	Silicic acid, lead salt Boron oxide (B2O3)	11120-22-2 1303-86-2
Brivo XR118	Silicic acid, lead salt	11120-22-2
WDR1	Silicic acid, lead salt Lead	11120-22-2 7439-92-1





## GE Healthcare

**Surya Kunduri**  
REACH Regulations Leader  
Product Compliance Engineering  
Suryadutt.Kunduri@ge.com  
M +33 664083106

**Yachun Du**  
Senior Architect  
GEHC X Ray Engineering  
Yachun.du@ge.com  
M +86 10 57083340

A GE Healthcare együttműködik a beszállítókkal annak biztosítása érdekében, hogy az Európai Unióban gyártott, az Európai Unióba importált, illetve a GE Healthcare termékek előállításánál felhasznált árucikkek megfeleljenek a REACH szabályozás (EK 1907/2006) 33-as cikkelyének.

A GE Healthcare tisztában van jogi kötelezettségeivel, és eleget tesz a REACH szabályozás 33-as cikkelye és 59-es cikkelye (különös aggodalomra okot adó anyagok (SVHC) jelöltlistájának publikálása) által előírtaknak.

A GE Healthcare árucikkek normál felhasználási körülmények között szándékosan nem bocsátanak ki anyagot.

A beszállítóinktól kapott aktuális tájékoztatás szerint ezek az anyagok 0,1%-nál nagyobb tömegkoncentrációban vannak jelen az alábbi termékekben:

Termék neve	Anyag neve	CAS-szám.
XR240amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Cadmium oxide (CdO)	1306-19-0
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro- 1,4,4a,5,6,6a,7,10,10a,11,12,12a- dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5- methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5- tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro- 1,3-dioxo-	552-30-7
	Lead	7439-92-1
Cadmium	7440-43-9	
XR220amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8



	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro- 1,4,4a,5,6,6a,7,10,10a,11,12,12a- dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5- methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5- tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro- 1,3-dioxo-	552-30-7
	Lead	7439-92-1
	Cadmium	7440-43-9
XR200amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro- 1,4,4a,5,6,6a,7,10,10a,11,12,12a- dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5- methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5- tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro- 1,3-dioxo-	552-30-7
	Lead	7439-92-1
	Cadmium	7440-43-9
Brivo XR285	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro- 1,4,4a,5,6,6a,7,10,10a,11,12,12a- dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5- methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5- tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro- 1,3-dioxo-	552-30-7
	Lead	7439-92-1



	Cadmium	7440-43-9
AMX 4/4+/700	Silicic acid, lead salt Boron oxide (B <sub>2</sub> O <sub>3</sub> ) Lead oxide (PbO)	11120-22-2 1303-86-2 1317-36-8
Discovery XR656	Lead 1,3-Isobenzofurandione, hexahydromethyl- Boron oxide (B <sub>2</sub> O <sub>3</sub> ) Lead titanium zirconium oxide (Pb(Ti,Zr)O <sub>3</sub> ) Silicic acid, lead salt	7439-92-1 25550-51-0 1303-86-2 12626-81-2 11120-22-2
Optima XR646	Lead oxide (PbO) Boron oxide (B <sub>2</sub> O <sub>3</sub> ) Lead titanium zirconium oxide (Pb(Ti,Zr)O <sub>3</sub> ) Silicic acid, lead salt Lead 1,3-Isobenzofurandione, hexahydromethyl- 1,3-Isobenzofurandione, hexahydro-5- methyl-	1317-36-8 1303-86-2 12626-81-2 11120-22-2 7439-92-1 25550-51-0 19438-60-9
Brivo XR575	Silicic acid, lead salt	11120-22-2
Proteus XR/a	Silicic acid, lead salt Boron oxide (B <sub>2</sub> O <sub>3</sub> ) Lead	11120-22-2 1303-86-2 7439-92-1
XR6000	Silicic acid, lead salt Boron oxide (B <sub>2</sub> O <sub>3</sub> )	11120-22-2 1303-86-2
Brivo XR118	Silicic acid, lead salt	11120-22-2
WDR1	Silicic acid, lead salt Lead	11120-22-2 7439-92-1



## GE Healthcare

**Surya Kunduri**  
REACH Regulations Leader  
Product Compliance Engineering  
Suryadutt.Kunduri@ge.com  
M +33 664083106

**Yachun Du**  
Senior Architect  
GEHC X Ray Engineering  
Yachun.du@ge.com  
M +86 10 57083340

GE Healthcare taħdem mal-fornituri tagħha biex tiżgura konformità mal-oġġetti importati jew manifatturati fl-Unjoni Ewropea li huma soġġetti għall-Artikolu 33 tar-Regolament REACH (KE-Nru 1907/2006), u jintużaw fil-produzzjoni tal-prodotti ta' GE Healthcare.

Fir-rigward tal-applikazzjoni tal-Artikolu 33 tar-Regolament REACH u l-pubblikazzjoni tal-Lista ta' Kandidati ta' Sustanzi ta' Tħassib Serju Ħafna (SVHC) skont l-Artikolu 59 tar-Regolament REACH, GE Healthcare hija konxja dwar l-obbligi legali tagħha u se tikkonforma magħhom.

L-oġġetti ta' GE Healthcare ma "jirrilaxxawx intenzjonalment" sustanzi f'kundizzjonijiet normali ta' użu. Abbażi tal-informazzjoni mill-fornituri tagħna sa issa, dawn is-sustanzi huma preżenti fil-prodotti li ġejjin f'koncentrazzjoni akbar mil-limitu ta' 0.1 % piż b'piż fil-livell tal-oġġett:

Isem il-prodott	Isem tas-sustanza	Nru CAS
XR240amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Cadmium oxide (CdO)	1306-19-0
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro- 1,4,4a,5,6,6a,7,10,10a,11,12,12a- dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5- methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5- tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro- 1,3-dioxo-	552-30-7
	Lead	7439-92-1
Cadmium	7440-43-9	
XR220amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8



	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro- 1,4,4a,5,6,6a,7,10,10a,11,12,12a- dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5- methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5- tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro- 1,3-dioxo-	552-30-7
	Lead	7439-92-1
	Cadmium	7440-43-9
XR200amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro- 1,4,4a,5,6,6a,7,10,10a,11,12,12a- dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5- methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5- tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro- 1,3-dioxo-	552-30-7
	Lead	7439-92-1
Cadmium	7440-43-9	
Brivo XR285	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro- 1,4,4a,5,6,6a,7,10,10a,11,12,12a- dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5- methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5- tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro- 1,3-dioxo-	552-30-7
	Lead	7439-92-1



	Cadmium	7440-43-9
AMX 4/4+/700	Silicic acid, lead salt Boron oxide (B <sub>2</sub> O <sub>3</sub> ) Lead oxide (PbO)	11120-22-2 1303-86-2 1317-36-8
Discovery XR656	Lead 1,3-Isobenzofurandione, hexahydromethyl- Boron oxide (B <sub>2</sub> O <sub>3</sub> ) Lead titanium zirconium oxide (Pb(Ti,Zr)O <sub>3</sub> ) Silicic acid, lead salt	7439-92-1 25550-51-0 1303-86-2 12626-81-2 11120-22-2
Optima XR646	Lead oxide (PbO) Boron oxide (B <sub>2</sub> O <sub>3</sub> ) Lead titanium zirconium oxide (Pb(Ti,Zr)O <sub>3</sub> ) Silicic acid, lead salt Lead 1,3-Isobenzofurandione, hexahydromethyl- 1,3-Isobenzofurandione, hexahydro-5- methyl-	1317-36-8 1303-86-2 12626-81-2 11120-22-2 7439-92-1 25550-51-0 19438-60-9
Brivo XR575	Silicic acid, lead salt	11120-22-2
Proteus XR/a	Silicic acid, lead salt Boron oxide (B <sub>2</sub> O <sub>3</sub> ) Lead	11120-22-2 1303-86-2 7439-92-1
XR6000	Silicic acid, lead salt Boron oxide (B <sub>2</sub> O <sub>3</sub> )	11120-22-2 1303-86-2
Brivo XR118	Silicic acid, lead salt	11120-22-2
WDR1	Silicic acid, lead salt Lead	11120-22-2 7439-92-1



## GE Healthcare

**Surya Kunduri**  
 REACH Regulations Leader  
 Product Compliance Engineering  
 Suryadutt.Kunduri@ge.com  
 M +33 664083106

**Yachun Du**  
 Senior Architect  
 GEHC X Ray Engineering  
 Yachun.du@ge.com  
 M +86 10 57083340

GE Healthcare werkt samen met zijn leveranciers om ervoor te zorgen dat artikelen die zijn geïmporteerd of geproduceerd binnen de Europese Unie voldoen aan de REACH-verordening (EG-nr. 1907/2006) artikel 33 en worden gebruikt bij de productie van GE Healthcare-producten.

GE Healthcare is op de hoogte van zijn wettelijke verplichtingen omtrent de toepassing van artikel 33 van de REACH-verordening en de publicatie van de Kandidaatslijst van zeer zorgwekkende stoffen volgens artikel 59 van de REACH-verordening, en zal deze naleven.

Onder normale omstandigheden geven de artikelen van GE Healthcare niet 'opzettelijk' stoffen af. Op basis van de huidige informatie van onze leveranciers zijn deze stoffen aanwezig in de volgende producten met een hogere concentratie dan de drempel van 0,1% gewicht per gewicht op artikelniveau:

Productnaam	Naam van de stof	CAS-nr.
XR240amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Cadmium oxide (CdO)	1306-19-0
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro- 1,4,4a,5,6,6a,7,10,10a,11,12,12a- dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5- methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5- tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro- 1,3-dioxo-	552-30-7
Lead	7439-92-1	
Cadmium	7440-43-9	
XR220amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8



	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro- 1,4,4a,5,6,6a,7,10,10a,11,12,12a- dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5- methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5- tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro- 1,3-dioxo-	552-30-7
	Lead	7439-92-1
	Cadmium	7440-43-9
XR200amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro- 1,4,4a,5,6,6a,7,10,10a,11,12,12a- dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5- methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5- tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro- 1,3-dioxo-	552-30-7
	Lead	7439-92-1
	Cadmium	7440-43-9
Brivo XR285	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro- 1,4,4a,5,6,6a,7,10,10a,11,12,12a- dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5- methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5- tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro- 1,3-dioxo-	552-30-7
	Lead	7439-92-1





	Cadmium	7440-43-9
AMX 4/4+/700	Silicic acid, lead salt Boron oxide (B <sub>2</sub> O <sub>3</sub> ) Lead oxide (PbO)	11120-22-2 1303-86-2 1317-36-8
Discovery XR656	Lead 1,3-Isobenzofurandione, hexahydromethyl- Boron oxide (B <sub>2</sub> O <sub>3</sub> ) Lead titanium zirconium oxide (Pb(Ti,Zr)O <sub>3</sub> ) Silicic acid, lead salt	7439-92-1 25550-51-0 1303-86-2 12626-81-2 11120-22-2
Optima XR646	Lead oxide (PbO) Boron oxide (B <sub>2</sub> O <sub>3</sub> ) Lead titanium zirconium oxide (Pb(Ti,Zr)O <sub>3</sub> ) Silicic acid, lead salt Lead 1,3-Isobenzofurandione, hexahydromethyl- 1,3-Isobenzofurandione, hexahydro-5- methyl-	1317-36-8 1303-86-2 12626-81-2 11120-22-2 7439-92-1 25550-51-0 19438-60-9
Brivo XR575	Silicic acid, lead salt	11120-22-2
Proteus XR/a	Silicic acid, lead salt Boron oxide (B <sub>2</sub> O <sub>3</sub> ) Lead	11120-22-2 1303-86-2 7439-92-1
XR6000	Silicic acid, lead salt Boron oxide (B <sub>2</sub> O <sub>3</sub> )	11120-22-2 1303-86-2
Brivo XR118	Silicic acid, lead salt	11120-22-2
WDR1	Silicic acid, lead salt Lead	11120-22-2 7439-92-1



## GE Healthcare

**Surya Kunduri**  
REACH Regulations Leader  
Product Compliance Engineering  
Suryadutt.Kunduri@ge.com  
M +33 664083106

**Yachun Du**  
Senior Architect  
GEHC X Ray Engineering  
Yachun.du@ge.com  
M +86 10 57083340

Firma GE Healthcare współpracuje ze swoimi dostawcami w celu zagwarantowania zgodności importowanych do Unii Europejskiej lub wytwarzanych na jej obszarze produktów podlegających artykułowi 33 rozporządzenia REACH (rozporządzenie WE nr 1907/2006), które są stosowane w procesie produkcji wyrobów firmy GE Healthcare.

Firma GE Healthcare ma świadomość prawnych zobowiązań wynikających z artykułu 33 rozporządzenia REACH i publikacji listy kandydackiej substancji stanowiących bardzo duże zagrożenie (SVHC), zgodnie z artykułem 59 rozporządzenia REACH, i będzie ich przestrzegać.

Prawidłowo użytkowanych produktów firmy GE Healthcare nie dotyczy zjawisko „zamierzonego uwalniania” substancji.

Z informacji przekazanych nam dotychczas przez naszych dostawców wynika, że wspomniane substancje występują w następujących produktach w stężeniu przekraczającym wartość graniczną wynoszącą 0,1% wagi produktu:

Nazwa produktu	Nazwa substancji	Nr CAS
XR240amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Cadmium oxide (CdO)	1306-19-0
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene,	13560-89-9
	1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro-	
	1,4,4a,5,6,6a,7,10,10a,11,12,12a-	
	dodecahydro-	
	1,3-Isobenzofurandione, hexahydro-5-	19438-60-9
	methyl-	
1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5-	2451-62-9	
tris(2-oxiranylmethyl)-		
Formaldehyde	50-00-0	
5-Isobenzofurancarboxylic acid, 1,3-dihydro-	552-30-7	
1,3-dioxo-		
Lead	7439-92-1	
Cadmium	7440-43-9	
XR220amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8



	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro- 1,4,4a,5,6,6a,7,10,10a,11,12,12a- dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5- methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5- tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro- 1,3-dioxo-	552-30-7
	Lead	7439-92-1
	Cadmium	7440-43-9
XR200amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro- 1,4,4a,5,6,6a,7,10,10a,11,12,12a- dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5- methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5- tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro- 1,3-dioxo-	552-30-7
	Lead	7439-92-1
	Cadmium	7440-43-9
Brivo XR285	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro- 1,4,4a,5,6,6a,7,10,10a,11,12,12a- dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5- methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5- tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro- 1,3-dioxo-	552-30-7
	Lead	7439-92-1



	Cadmium	7440-43-9
AMX 4/4+/700	Silicic acid, lead salt Boron oxide (B2O3) Lead oxide (PbO)	11120-22-2 1303-86-2 1317-36-8
Discovery XR656	Lead 1,3-Isobenzofurandione, hexahydromethyl- Boron oxide (B2O3) Lead titanium zirconium oxide (Pb(Ti,Zr)O3) Silicic acid, lead salt	7439-92-1 25550-51-0 1303-86-2 12626-81-2 11120-22-2
Optima XR646	Lead oxide (PbO) Boron oxide (B2O3) Lead titanium zirconium oxide (Pb(Ti,Zr)O3) Silicic acid, lead salt Lead 1,3-Isobenzofurandione, hexahydromethyl- 1,3-Isobenzofurandione, hexahydro-5- methyl-	1317-36-8 1303-86-2 12626-81-2 11120-22-2 7439-92-1 25550-51-0 19438-60-9
Brivo XR575	Silicic acid, lead salt	11120-22-2
Proteus XR/a	Silicic acid, lead salt Boron oxide (B2O3) Lead	11120-22-2 1303-86-2 7439-92-1
XR6000	Silicic acid, lead salt Boron oxide (B2O3)	11120-22-2 1303-86-2
Brivo XR118	Silicic acid, lead salt	11120-22-2
WDR1	Silicic acid, lead salt Lead	11120-22-2 7439-92-1



## GE Healthcare

**Surya Kunduri**  
REACH Regulations Leader  
Product Compliance Engineering  
Suryadutt.Kunduri@ge.com  
M +33 664083106

**Yachun Du**  
Senior Architect  
GEHC X Ray Engineering  
Yachun.du@ge.com  
M +86 10 57083340

A GE Healthcare trabalha com os seus fornecedores para assegurar a conformidade dos artigos importados ou fabricados dentro da União Europeia sujeitos ao artigo 33.º do regulamento REACH (CE – N.º 1907/2006) e que são utilizados no fabrico de produtos da GE Healthcare.

Relativamente à aplicação do artigo 33.º do regulamento REACH e à publicação da Lista de substâncias que suscitam elevada preocupação (SVHC), de acordo com o artigo 59.º do regulamento REACH, a GE Healthcare tem conhecimento das suas obrigações legais e agirá em conformidade com as mesmas. Em condições normais de utilização, os artigos da GE Healthcare não "libertam substâncias intencionalmente".

Com base nas informações dos nossos fornecedores, até à data, estas substâncias estão presentes nos seguintes produtos com uma concentração superior ao limite de 0,1% de massa por massa ao nível do artigo:

Nome do produto	Nome da substância	N.º CAS
XR240amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Cadmium oxide (CdO)	1306-19-0
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene,	13560-89-9
	1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro-	
	1,4,4a,5,6,6a,7,10,10a,11,12,12a-	
	dodecahydro-	
	1,3-Isobenzofurandione, hexahydro-5-	19438-60-9
	methyl-	
1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5-	2451-62-9	
tris(2-oxiranylmethyl)-		
Formaldehyde	50-00-0	
5-Isobenzofurancarboxylic acid, 1,3-dihydro-	552-30-7	
1,3-dioxo-		
Lead	7439-92-1	
Cadmium	7440-43-9	
XR220amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8



	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro- 1,4,4a,5,6,6a,7,10,10a,11,12,12a- dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5- methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5- tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro- 1,3-dioxo-	552-30-7
	Lead	7439-92-1
	Cadmium	7440-43-9
XR200amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro- 1,4,4a,5,6,6a,7,10,10a,11,12,12a- dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5- methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5- tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro- 1,3-dioxo-	552-30-7
	Lead	7439-92-1
	Cadmium	7440-43-9
Brivo XR285	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro- 1,4,4a,5,6,6a,7,10,10a,11,12,12a- dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5- methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5- tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro- 1,3-dioxo-	552-30-7
	Lead	7439-92-1



	Cadmium	7440-43-9
AMX 4/4+/700	Silicic acid, lead salt Boron oxide (B <sub>2</sub> O <sub>3</sub> ) Lead oxide (PbO)	11120-22-2 1303-86-2 1317-36-8
Discovery XR656	Lead 1,3-Isobenzofurandione, hexahydromethyl- Boron oxide (B <sub>2</sub> O <sub>3</sub> ) Lead titanium zirconium oxide (Pb(Ti,Zr)O <sub>3</sub> ) Silicic acid, lead salt	7439-92-1 25550-51-0 1303-86-2 12626-81-2 11120-22-2
Optima XR646	Lead oxide (PbO) Boron oxide (B <sub>2</sub> O <sub>3</sub> ) Lead titanium zirconium oxide (Pb(Ti,Zr)O <sub>3</sub> ) Silicic acid, lead salt Lead 1,3-Isobenzofurandione, hexahydromethyl- 1,3-Isobenzofurandione, hexahydro-5- methyl-	1317-36-8 1303-86-2 12626-81-2 11120-22-2 7439-92-1 25550-51-0 19438-60-9
Brivo XR575	Silicic acid, lead salt	11120-22-2
Proteus XR/a	Silicic acid, lead salt Boron oxide (B <sub>2</sub> O <sub>3</sub> ) Lead	11120-22-2 1303-86-2 7439-92-1
XR6000	Silicic acid, lead salt Boron oxide (B <sub>2</sub> O <sub>3</sub> )	11120-22-2 1303-86-2
Brivo XR118	Silicic acid, lead salt	11120-22-2
WDR1	Silicic acid, lead salt Lead	11120-22-2 7439-92-1



## GE Healthcare

**Surya Kunduri**  
REACH Regulations Leader  
Product Compliance Engineering  
Suryadutt.Kunduri@ge.com  
M +33 664083106

**Yachun Du**  
Senior Architect  
GEHC X Ray Engineering  
Yachun.du@ge.com  
M +86 10 57083340

GE Healthcare lucrează cu furnizorii săi pentru a asigura conformitatea articolelor importate sau fabricate în Uniunea Europeană care fac obiectul regulamentului REACH (CE-nr. 1907/2006), articolul 33, și care sunt utilizate în producția de produse GE Healthcare.

În ceea ce privește aplicarea articolului 33 din regulamentul REACH și publicarea listei de substanțe care prezintă motive de îngrijorare deosebită (SVHC) în conformitate cu articolul 59 din regulamentul REACH, GE Healthcare are cunoștință de obligațiile legale și le va respecta.

Articolele GE Healthcare nu eliberează în mod intenționat substanțele în condiții normale de utilizare.

Pe baza informațiilor furnizate de furnizorii noștri până în prezent, aceste substanțe sunt prezente în următoarele produse într-o concentrație mai mare decât pragul de 0,1% în greutate la nivel de articol:

Numele produsului	Denumirea substanței	Nr. CAS
XR240amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Cadmium oxide (CdO)	1306-19-0
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene,	13560-89-9
	1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro-	
	1,4,4a,5,6,6a,7,10,10a,11,12,12a-	
	dodecahydro-	
	1,3-Isobenzofurandione, hexahydro-5-	19438-60-9
	methyl-	
1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5-	2451-62-9	
tris(2-oxiranylmethyl)-		
Formaldehyde	50-00-0	
5-Isobenzofurancarboxylic acid, 1,3-dihydro-	552-30-7	
1,3-dioxo-		
Lead	7439-92-1	
Cadmium	7440-43-9	
XR220amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8





	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro- 1,4,4a,5,6,6a,7,10,10a,11,12,12a- dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5- methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5- tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro- 1,3-dioxo-	552-30-7
	Lead	7439-92-1
	Cadmium	7440-43-9
XR200amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro- 1,4,4a,5,6,6a,7,10,10a,11,12,12a- dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5- methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5- tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro- 1,3-dioxo-	552-30-7
	Lead	7439-92-1
	Cadmium	7440-43-9
Brivo XR285	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro- 1,4,4a,5,6,6a,7,10,10a,11,12,12a- dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5- methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5- tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro- 1,3-dioxo-	552-30-7
	Lead	7439-92-1



	Cadmium	7440-43-9
AMX 4/4+/700	Silicic acid, lead salt Boron oxide (B <sub>2</sub> O <sub>3</sub> ) Lead oxide (PbO)	11120-22-2 1303-86-2 1317-36-8
Discovery XR656	Lead 1,3-Isobenzofurandione, hexahydromethyl- Boron oxide (B <sub>2</sub> O <sub>3</sub> ) Lead titanium zirconium oxide (Pb(Ti,Zr)O <sub>3</sub> ) Silicic acid, lead salt	7439-92-1 25550-51-0 1303-86-2 12626-81-2 11120-22-2
Optima XR646	Lead oxide (PbO) Boron oxide (B <sub>2</sub> O <sub>3</sub> ) Lead titanium zirconium oxide (Pb(Ti,Zr)O <sub>3</sub> ) Silicic acid, lead salt Lead 1,3-Isobenzofurandione, hexahydromethyl- 1,3-Isobenzofurandione, hexahydro-5- methyl-	1317-36-8 1303-86-2 12626-81-2 11120-22-2 7439-92-1 25550-51-0 19438-60-9
Brivo XR575	Silicic acid, lead salt	11120-22-2
Proteus XR/a	Silicic acid, lead salt Boron oxide (B <sub>2</sub> O <sub>3</sub> ) Lead	11120-22-2 1303-86-2 7439-92-1
XR6000	Silicic acid, lead salt Boron oxide (B <sub>2</sub> O <sub>3</sub> )	11120-22-2 1303-86-2
Brivo XR118	Silicic acid, lead salt	11120-22-2
WDR1	Silicic acid, lead salt Lead	11120-22-2 7439-92-1



## GE Healthcare

**Surya Kunduri**  
REACH Regulations Leader  
Product Compliance Engineering  
Suryadutt.Kunduri@ge.com  
M +33 664083106

**Yachun Du**  
Senior Architect  
GEHC X Ray Engineering  
Yachun.du@ge.com  
M +86 10 57083340

Spoločnosť GE Healthcare spolupracuje so svojimi dodávateľmi na zabezpečení zhody výrobkov dovážaných alebo vyrábaných v Európskej únii, na ktoré sa vzťahuje nariadenie REACH (ES – č. 1907/2006), článok 33, a ktoré sa používajú pri výrobe produktov GE Healthcare.

Pokiaľ ide o uplatňovanie článku 33 nariadenia REACH a zverejnenie zoznamu navrhovaných látok vzbudzujúcich veľmi veľké obavy (SVHC) podľa článku 59 nariadenia REACH, spoločnosť GE Healthcare si je vedomá svojich zákonných povinností a bude ich dodržiavať.

Produkty GE Healthcare za normálnych podmienok používania „zámerne neuvolňujú“ látky.

Na základe doterajších informácií od našich dodávateľov sú tieto látky prítomné v nasledujúcich produktoch v koncentrácii vyššej ako prahová hodnota 0,1 % proporcionálnej hmotnosti na úrovni výrobku:

Názov produktu	Názov látky	Číslo CAS
XR240amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Cadmium oxide (CdO)	1306-19-0
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro-1,4,4a,5,6,6a,7,10,10a,11,12,12a-dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5-methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5-tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro-1,3-dioxo-	552-30-7
	Lead	7439-92-1
Cadmium	7440-43-9	
XR220amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8



	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro- 1,4,4a,5,6,6a,7,10,10a,11,12,12a- dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5- methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5- tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro- 1,3-dioxo-	552-30-7
	Lead	7439-92-1
	Cadmium	7440-43-9
XR200amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro- 1,4,4a,5,6,6a,7,10,10a,11,12,12a- dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5- methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5- tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro- 1,3-dioxo-	552-30-7
	Lead	7439-92-1
	Cadmium	7440-43-9
Brivo XR285	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro- 1,4,4a,5,6,6a,7,10,10a,11,12,12a- dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5- methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5- tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro- 1,3-dioxo-	552-30-7
	Lead	7439-92-1



	Cadmium	7440-43-9
AMX 4/4+/700	Silicic acid, lead salt Boron oxide (B <sub>2</sub> O <sub>3</sub> ) Lead oxide (PbO)	11120-22-2 1303-86-2 1317-36-8
Discovery XR656	Lead 1,3-Isobenzofurandione, hexahydromethyl- Boron oxide (B <sub>2</sub> O <sub>3</sub> ) Lead titanium zirconium oxide (Pb(Ti,Zr)O <sub>3</sub> ) Silicic acid, lead salt	7439-92-1 25550-51-0 1303-86-2 12626-81-2 11120-22-2
Optima XR646	Lead oxide (PbO) Boron oxide (B <sub>2</sub> O <sub>3</sub> ) Lead titanium zirconium oxide (Pb(Ti,Zr)O <sub>3</sub> ) Silicic acid, lead salt Lead 1,3-Isobenzofurandione, hexahydromethyl- 1,3-Isobenzofurandione, hexahydro-5- methyl-	1317-36-8 1303-86-2 12626-81-2 11120-22-2 7439-92-1 25550-51-0 19438-60-9
Brivo XR575	Silicic acid, lead salt	11120-22-2
Proteus XR/a	Silicic acid, lead salt Boron oxide (B <sub>2</sub> O <sub>3</sub> ) Lead	11120-22-2 1303-86-2 7439-92-1
XR6000	Silicic acid, lead salt Boron oxide (B <sub>2</sub> O <sub>3</sub> )	11120-22-2 1303-86-2
Brivo XR118	Silicic acid, lead salt	11120-22-2
WDR1	Silicic acid, lead salt Lead	11120-22-2 7439-92-1



## GE Healthcare

**Surya Kunduri**  
REACH Regulations Leader  
Product Compliance Engineering  
Suryadutt.Kunduri@ge.com  
M +33 664083106

**Yachun Du**  
Senior Architect  
GEHC X Ray Engineering  
Yachun.du@ge.com  
M +86 10 57083340

GE Healthcare v sodelovanju s svojimi dobavitelji zagotavlja skladnost izdelkov, uvoženih ali proizvedenih v Evropski uniji, za katere velja člen 33 uredbe REACH (št. ES 1907/2006) in ki se uporabljajo pri proizvodnji izdelkov družbe GE Healthcare.

Družba GE Healthcare se zaveda svojih pravnih obveznosti v zvezi z uporabo člena 33 uredbe REACH in objavo seznama kandidatnih snovi, ki vzbujajo veliko skrb (SVHC), v skladu s členom 59 uredbe REACH in bo svoje dolžnosti izpolnjevala.

Izdelki družbe GE Healthcare pod normalnimi pogoji uporabe ne sproščajo snovi "namerno".

Na podlagi dosedanjih informacij naših dobaviteljev so te snovi prisotne v naslednjih proizvodih s koncentracijo, ki je večja od mejne vrednosti 0,1 % teže izdelka na ravni izdelka:

Ime izdelka	Ime snovi	Št. CAS
XR240amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Cadmium oxide (CdO)	1306-19-0
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro-1,4,4a,5,6,6a,7,10,10a,11,12,12a-dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5-methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5-tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro-1,3-dioxo-	552-30-7
Lead	7439-92-1	
Cadmium	7440-43-9	
XR220amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro-1,4,4a,5,6,6a,7,10,10a,11,12,12a-dodecahydro-	13560-89-9



	1,3-Isobenzofurandione, hexahydro-5-methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5-tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro-1,3-dioxo-	552-30-7
	Lead	7439-92-1
	Cadmium	7440-43-9
XR200amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro-1,4,4a,5,6,6a,7,10,10a,11,12,12a-dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5-methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5-tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro-1,3-dioxo-	552-30-7
	Lead	7439-92-1
	Cadmium	7440-43-9
Brivo XR285	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro-1,4,4a,5,6,6a,7,10,10a,11,12,12a-dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5-methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5-tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro-1,3-dioxo-	552-30-7
	Lead	7439-92-1
	Cadmium	7440-43-9
AMX 4/4+/700	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2



	Lead oxide (PbO)	1317-36-8
Discovery XR656	Lead 1,3-Isobenzofurandione, hexahydromethyl- Boron oxide (B2O3) Lead titanium zirconium oxide (Pb(Ti,Zr)O3) Silicic acid, lead salt	7439-92-1 25550-51-0 1303-86-2 12626-81-2 11120-22-2
Optima XR646	Lead oxide (PbO) Boron oxide (B2O3) Lead titanium zirconium oxide (Pb(Ti,Zr)O3) Silicic acid, lead salt Lead 1,3-Isobenzofurandione, hexahydromethyl- 1,3-Isobenzofurandione, hexahydro-5- methyl-	1317-36-8 1303-86-2 12626-81-2 11120-22-2 7439-92-1 25550-51-0 19438-60-9
Brivo XR575	Silicic acid, lead salt	11120-22-2
Proteus XR/a	Silicic acid, lead salt Boron oxide (B2O3) Lead	11120-22-2 1303-86-2 7439-92-1
XR6000	Silicic acid, lead salt Boron oxide (B2O3)	11120-22-2 1303-86-2
Brivo XR118	Silicic acid, lead salt	11120-22-2
WDR1	Silicic acid, lead salt Lead	11120-22-2 7439-92-1





## GE Healthcare

**Surya Kunduri**  
REACH Regulations Leader  
Product Compliance Engineering  
Suryadutt.Kunduri@ge.com  
M +33 664083106

**Yachun Du**  
Senior Architect  
GEHC X Ray Engineering  
Yachun.du@ge.com  
M +86 10 57083340

GE Healthcare takaa yhdessä tavarantoimittajiensa kanssa REACH-asetuksen (EY N:o 1907/2006) 33 artiklan alaisten Euroopan unionista tuotujen tai sen alueella valmistettujen sekä GE Healthcaren tuotteiden valmistuksessa käytettyjen tuotteiden säädöstenmukaisuuden.

Koskien REACH-asetuksen 33 artiklan toimeenpanoa ja REACH-asetuksen 59 artiklan mukaisesti julkaistua Ehdokasluetteloa erityistä huolta aiheuttavista aineista (Candidate List of Substances of Very High Concern, SVHC) GE Healthcare tietää lakisäätteiset velvollisuutensa ja noudattaa niitä.

GE Healthcaren tuotteista ei tarkoituksellisesti vapaudu aineita normaaleissa käyttöolosuhteissa.

Tavarantoimittajilta näiden tietojen julkaisuajankohtaan mennessä saatujen tietojen perusteella kyseisten aineiden pitoisuus ylittää 0,1 painoprosentin raja-arvon esinettä kohden seuraavissa tuotteissa:

Tuotteen nimi	Aineen nimi	CAS-nro
XR240amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Cadmium oxide (CdO)	1306-19-0
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene,	13560-89-9
	1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro-	
	1,4,4a,5,6,6a,7,10,10a,11,12,12a-	
	dodecahydro-	
	1,3-Isobenzofurandione, hexahydro-5-	19438-60-9
	methyl-	
1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5-	2451-62-9	
tris(2-oxiranylmethyl)-		
Formaldehyde	50-00-0	
5-Isobenzofurancarboxylic acid, 1,3-dihydro-	552-30-7	
1,3-dioxo-		
Lead	7439-92-1	
Cadmium	7440-43-9	
XR220amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8



	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro- 1,4,4a,5,6,6a,7,10,10a,11,12,12a- dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5- methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5- tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro- 1,3-dioxo-	552-30-7
	Lead	7439-92-1
	Cadmium	7440-43-9
XR200amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro- 1,4,4a,5,6,6a,7,10,10a,11,12,12a- dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5- methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5- tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro- 1,3-dioxo-	552-30-7
	Lead	7439-92-1
	Cadmium	7440-43-9
Brivo XR285	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro- 1,4,4a,5,6,6a,7,10,10a,11,12,12a- dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5- methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5- tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro- 1,3-dioxo-	552-30-7
	Lead	7439-92-1



	Cadmium	7440-43-9
AMX 4/4+/700	Silicic acid, lead salt Boron oxide (B <sub>2</sub> O <sub>3</sub> ) Lead oxide (PbO)	11120-22-2 1303-86-2 1317-36-8
Discovery XR656	Lead 1,3-Isobenzofurandione, hexahydromethyl- Boron oxide (B <sub>2</sub> O <sub>3</sub> ) Lead titanium zirconium oxide (Pb(Ti,Zr)O <sub>3</sub> ) Silicic acid, lead salt	7439-92-1 25550-51-0 1303-86-2 12626-81-2 11120-22-2
Optima XR646	Lead oxide (PbO) Boron oxide (B <sub>2</sub> O <sub>3</sub> ) Lead titanium zirconium oxide (Pb(Ti,Zr)O <sub>3</sub> ) Silicic acid, lead salt Lead 1,3-Isobenzofurandione, hexahydromethyl- 1,3-Isobenzofurandione, hexahydro-5- methyl-	1317-36-8 1303-86-2 12626-81-2 11120-22-2 7439-92-1 25550-51-0 19438-60-9
Brivo XR575	Silicic acid, lead salt	11120-22-2
Proteus XR/a	Silicic acid, lead salt Boron oxide (B <sub>2</sub> O <sub>3</sub> ) Lead	11120-22-2 1303-86-2 7439-92-1
XR6000	Silicic acid, lead salt Boron oxide (B <sub>2</sub> O <sub>3</sub> )	11120-22-2 1303-86-2
Brivo XR118	Silicic acid, lead salt	11120-22-2
WDR1	Silicic acid, lead salt Lead	11120-22-2 7439-92-1



## GE Healthcare

**Surya Kunduri**  
REACH Regulations Leader  
Product Compliance Engineering  
Suryadutt.Kunduri@ge.com  
M +33 664083106

**Yachun Du**  
Senior Architect  
GEHC X Ray Engineering  
Yachun.du@ge.com  
M +86 10 57083340

GE Healthcare samarbetar med sina leverantörer för att säkerställa överensstämmelse för produkter som importeras till eller tillverkas inom EU, omfattas av REACH-förordningen (EG nr. 1907/2006), artikel 33, och används under produktionen av GE Healthcares produkter.

Gällande tillämpningen av artikel 33 i REACH-förordningen och utgivningen av kandidatförteckningen över SVHC-ämnen (Substances of Very High Concern, ämnen som inger mycket stora betänkligheter) i enlighet med artikel 59 i REACH-förordningen är GE Healthcare medvetna om sina juridiska skyldigheter och kommer att leva upp till dem.

GE Healthcares produkter avger inga "avsiktliga utsläpp" vid normal användning.

Baserat på nuvarande information från våra leverantörer finns de här substanserna i nivåer som överskrider tröskelvärdet på 0,1 % vikt/volym i följande produkter:

Produktnamn	Ämnets namn	CAS-nr
XR240amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Cadmium oxide (CdO)	1306-19-0
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene,	13560-89-9
	1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro-	
	1,4,4a,5,6,6a,7,10,10a,11,12,12a-	
	dodecahydro-	
	1,3-Isobenzofurandione, hexahydro-5-	19438-60-9
	methyl-	
1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5-	2451-62-9	
tris(2-oxiranylmethyl)-		
Formaldehyde	50-00-0	
5-Isobenzofurancarboxylic acid, 1,3-dihydro-	552-30-7	
1,3-dioxo-		
Lead	7439-92-1	
Cadmium	7440-43-9	
XR220amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8



	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro- 1,4,4a,5,6,6a,7,10,10a,11,12,12a- dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5- methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5- tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro- 1,3-dioxo-	552-30-7
	Lead	7439-92-1
	Cadmium	7440-43-9
XR200amx	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro- 1,4,4a,5,6,6a,7,10,10a,11,12,12a- dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5- methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5- tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro- 1,3-dioxo-	552-30-7
	Lead	7439-92-1
	Cadmium	7440-43-9
Brivo XR285	Silicic acid, lead salt	11120-22-2
	Boron oxide (B2O3)	1303-86-2
	Lead oxide (PbO)	1317-36-8
	1,4:7,10-Dimethanodibenzo[a,e]cyclooctene, 1,2,3,4,7,8,9,10,13,13,14,14-dodecachloro- 1,4,4a,5,6,6a,7,10,10a,11,12,12a- dodecahydro-	13560-89-9
	1,3-Isobenzofurandione, hexahydro-5- methyl-	19438-60-9
	1,3,5-Triazine-2,4,6(1H,3H,5H)-trione, 1,3,5- tris(2-oxiranylmethyl)-	2451-62-9
	Formaldehyde	50-00-0
	5-Isobenzofurancarboxylic acid, 1,3-dihydro- 1,3-dioxo-	552-30-7
	Lead	7439-92-1



	Cadmium	7440-43-9
AMX 4/4+/700	Silicic acid, lead salt Boron oxide (B <sub>2</sub> O <sub>3</sub> ) Lead oxide (PbO)	11120-22-2 1303-86-2 1317-36-8
Discovery XR656	Lead 1,3-Isobenzofurandione, hexahydromethyl- Boron oxide (B <sub>2</sub> O <sub>3</sub> ) Lead titanium zirconium oxide (Pb(Ti,Zr)O <sub>3</sub> ) Silicic acid, lead salt	7439-92-1 25550-51-0 1303-86-2 12626-81-2 11120-22-2
Optima XR646	Lead oxide (PbO) Boron oxide (B <sub>2</sub> O <sub>3</sub> ) Lead titanium zirconium oxide (Pb(Ti,Zr)O <sub>3</sub> ) Silicic acid, lead salt Lead 1,3-Isobenzofurandione, hexahydromethyl- 1,3-Isobenzofurandione, hexahydro-5- methyl-	1317-36-8 1303-86-2 12626-81-2 11120-22-2 7439-92-1 25550-51-0 19438-60-9
Brivo XR575	Silicic acid, lead salt	11120-22-2
Proteus XR/a	Silicic acid, lead salt Boron oxide (B <sub>2</sub> O <sub>3</sub> ) Lead	11120-22-2 1303-86-2 7439-92-1
XR6000	Silicic acid, lead salt Boron oxide (B <sub>2</sub> O <sub>3</sub> )	11120-22-2 1303-86-2
Brivo XR118	Silicic acid, lead salt	11120-22-2
WDR1	Silicic acid, lead salt Lead	11120-22-2 7439-92-1